NPPA sends back over 200 FDC Applications

  • News
  • March 31, 2016

NEW DELHI
India’s drug pricing watchdog National Pharmaceutical Pricing Authority (NPPA) has moved in to back the health ministry in its efforts to check “irrational” fixed dose combinations (FDCs) it will review afresh all new applications for price fixations of FDC and examine their safety and efficacy.NPPA has also brought under the lens third-party drug makers and pharma companies that outsource to them to check irrational FDCs and spurious drugs. FDCs are cocktail drugs that contain two or more therapeutic ingredients in one dose. Many popular cough syrups, painkillers and antibiotics are FDC brands. NPPA has sent back more than 200 FDC price fixation applications, instructing manufacturing and marketing companies to apply again with a declaration that their formulations are not “irrational.

 

All manufacturers/marketing companies (whose cases have been rejected by NPPA so far) are advised to apply afresh… along with documents/information required as per revised check list, stated an NPPA notification dated March 8. We are taking cognizance of the fact that no irrational FDCs should get a price fixed by us and get legitimised in an indirect manner,” said Singh. “NPPA is concerned only with the pricing part (of this issue), and we are not declaring these FDCs rational or irrational .

  • Related Posts

    MedTech Zone AMTZ Puts Vizag on the Science Map of India

    Vizag Science &Technology Cluster rated as one of the India’s Strategic Innovation Hubs Visakhapatnam, June 28 – In a significant boost to Vizag’s growing scientific stature, the Andhra Pradesh MedTech…

    • News
    • May 27, 2025
    • 292 views
    Ramping Up Community for JeevanRaksha during Disasters

    CBDM India 2025 will Champion Health Resilience and Local Response Bengaluru: As India and its neighbours continue to confront the double threat of increasing natural disasters and unpredictable man-made crises—including…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

    Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

    10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

    10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra

    Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra